William R. Reid
Dilworth IP
Articles
Pain Treatment, Kidney Failure, and §101
USA - May 7 2019 In Endo Pharmaceuticals Inc. v. Teva the Federal Circuit has further clarified the patent eligibility of treatment methods which include natural…
Déjà vu at the Federal Circuit: Personal Web Technologies, LLC, v. Apple, Inc.
USA - April 9 2019 There is a scene in the Big Lebowski where the Dude complains about the lousy day he just had as he tosses down some snacks at a bowling alley bar…
Lead Compound Analysis in Mylan v. RCT
USA - March 19 2019 Lead compound analysis (LCA) has been used in the evaluation of chemical compound Obviousness for the past 20 years.[1] This approach supplemented the…
Obviousness, Prodrugs and the Rule of 5: Amerigen Pharmaceuticals Limited v. UCB Pharma GmbH
USA - February 7 2019 In Amerigen Pharmaceuticals Limited v. UCB Pharma GMBH, 2017-2596 (Fed. Cir. January 11, 2019), the Federal Circuit upheld the Board’s IPR finding…
Assignor Estoppel & Inter-Partes Review: Arista Networks, Inc. v. Cisco Systems, Inc.
USA - November 13 2018 Arista Networks, Inc. (Arista) petitioned for an IPR of Cisco Systems, Inc.’s (“Cisco”) patent, U.S. 7,340,597, relating to protecting computer…
